Chugai Applies For Additional Indication For Avastin For Recurrent Glioblastoma
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceuticals announced Sept. 19 that it has filed an application for an additional indication for an intravenous infusion of anti-cancer drug Avastin (bevacizumab) for recurrent glioblastoma.